TITLE:
Interferon Gamma-1b by Inhalation for the Treatment of Patients With Cystic Fibrosis

CONDITION:
Cystic Fibrosis

INTERVENTION:
interferon gamma-1b

SUMMARY:

      The purpose of this research study is to evaluate the safety and effectiveness of Interferon
      gamma-1b (IFN-g 1b) on lung function when given to patients with cystic fibrosis by
      inhalation (breathed into the lungs) three times a week for 12 weeks.

      The FDA has not approved Interferon gamma-1b for use with cystic fibrosis patients, which is
      the condition being examined in this study.
    

DETAILED DESCRIPTION:
NONE

ELIGIBILITY:
Gender: All
Age: 12 Years to N/A
Criteria:

        Key inclusion criteria:

          -  At least 12 years of age

          -  Diagnosis of cystic fibrosis with mild to moderate pulmonary impairment

          -  Must be receiving ongoing chronic treatment with TOBI (inhaled tobramycin) OR not
             receiving ongoing chronic treatment with TOBI and no use of TOBI or other inhaled
             antibiotic within 4 weeks prior to study drug administration

          -  Other specific diagnostic indicators of CF and other factors must meet minimum
             requirements.
      
